Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients : a systematic literature review and network meta-analysis by Laskier, V. et al.
This is a repository copy of Effectiveness and safety of betrixaban extended prophylaxis 
for venous thromboembolism compared with standard-duration prophylaxis intervention in 
acute medically ill patients : a systematic literature review and network meta-analysis.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/150157/
Version: Accepted Version
Article:
Laskier, V., Guy, H., Fisher, M. et al. (4 more authors) (2019) Effectiveness and safety of 
betrixaban extended prophylaxis for venous thromboembolism compared with 
standard-duration prophylaxis intervention in acute medically ill patients : a systematic 
literature review and network meta-analysis. Journal of Medical Economics. ISSN 
1369-6998 
https://doi.org/10.1080/13696998.2019.1645679
This is an Accepted Manuscript of an article published by Taylor & Francis in Journal of 
Medical Economics on 17th July 2019, available online: 
http://www.tandfonline.com/10.1080/13696998.2019.1645679
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1 
 
Effectiveness and safety of betrixaban extended prophylaxis for venous 
thromboembolism compared with standard-duration prophylaxis 
intervention in acute medically ill patients: a systematic literature review 
and network meta-analysis 
Vicki Laskiera*, Holly Guya, Mark Fishera, W. Richey Neumanb, Iwona Buciorb, 
Alexander T. Cohenc, Shijie Rend 
aFIECON Ltd, Hertfordshire, St Albans, UK; bPortola Pharmaceuticals, Inc., South San 
Francisco, CA, USA; c*X\¶VDQG6W7KRPDV¶+RVSLWDOV/RQGRQ8.dThe University of 
Sheffield, Sheffield, UK 
*Vicki, Laskier, FIECON Ltd 
Hodgkin Huxley House 
30 Farringdon Lane 
London, EC1R 3AW 
Tel: +44 1727 225 601, Email: vicki.laskier@fiecon.com 
LinkedIn: https://uk.linkedin.com/in/victoria-laskier  
  
2 
 
Effectiveness and safety of betrixaban extended prophylaxis for venous 
thromboembolism compared with standard-duration prophylaxis 
intervention in acute medically ill patients: a systematic literature review 
and network meta-analysis 
Aims: To determine the clinical effectiveness and safety of venous thromboembolism 
(VTE) prophylaxis using  United States- (US) and Europe-approved anticoagulants 
relative to extended-duration VTE prophylaxis with betrixaban. Low molecular weight 
heparins (LMWHs), unfractionated heparin (UFH), fondaparinux sodium and placebo 
were each compared to betrixaban, as standard-duration VTE prophylaxis for 
hospitalized, nonsurgical patients with acute medical illness at risk of VTE. 
Materials and methods: A systematic literature review was conducted up to June 2019 
to identify randomized controlled trials (RCTs) of VTE prophylaxis in hospitalized, 
nonsurgical patients with acute medical illness at risk of VTE. Studies that reported the 
occurrence of VTE events (including death) and, where possible, major bleeding, from 
treatment initiation to 20-50 days thereafter were retrieved and extracted. A Bayesian 
fixed effect network meta-analysis was used to estimate efficacy and safety of 
betrixaban compared with standard-duration VTE prophylaxis. 
Results: Seven RCTs were analyzed, which compared betrixaban with LMWHs, UFH, 
fondaparinux sodium, or placebo. There were significantly higher odds (median odds 
[95% credible interval]) of VTE with LMWHs (1.38 [1.12-1.70]), UFH (1.60 [1.05-
2.46]) and placebo (2.37 [1.55-3.66]) compared with betrixaban. There were 
significantly higher odds of VTE-related death with placebo (7.76 [2.14-34.40]) 
compared with betrixaban. No significant differences were observed for the odds of 
major bleeding with all comparators, VTE-related death with any active standard-
duration VTE prophylaxis, or of VTE with fondaparinux sodium, compared with 
betrixaban. 
Limitations and conclusions: In this indirect comparison, betrixaban was shown to be 
an effective regimen with relative benefits compared with LMWHs and UFH. This 
indicates that betrixaban could reduce the burden of VTE in at-risk hospitalized 
patients with acute medical illness who need extended prophylaxis, though without 
direct comparative evidence, stronger conclusions cannot be drawn. 
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Introduction 
Venous thromboembolism (VTE) is a common cause of morbidity and mortality, particularly 
in patients hospitalized with an acute medical illness. A model developed in the United States 
(US) estimated that 196,134 VTE-related events occurred in US acutely ill hospitalized 
patients in 2003.[1] Approximately one third of all symptomatic VTE results in death.[2] 
Though many patients survive VTE, some require intensive care and treatment which can last 
for several months. Furthermore, not all survivors of VTE are restored to their previous state 
of health; approximately 30% of surviving patients will experience a recurrent VTE episode 
within 10 years of their first episode.[3] Additionally, surviving patients can experience 
severe complications including chronic thromboembolic pulmonary hypertension (CTEPH) 
and post-thrombotic syndrome (PTS) which reduce quality of life and are costly to treat.[4], 
[5] 
Though the highest risk of VTE in the acute medically ill population occurs during 
hospitalization, the risk persists following discharge. It is reported that 45%-75% of all VTEs 
in the acute medically ill population occur post-discharge.[6]±[9] Therefore, it is necessary 
that thromboprophylaxis continues beyond hospitalization in many patients, when standard-
duration thromboprophylaxis typically ends, to minimize the risk of VTE. This is particularly 
important among those who have multiple risk factors for VTE, including previous 
hospitalization for an acute medical illness, increased age, reduced mobility, history of cancer 
or VTE, and obesity. Previous studies have investigated extended-duration VTE prophylaxis 
in patients hospitalized with an acute medical illness to address the risk of VTE after hospital 
discharge.[10]±[12] However, in these studies extended-duration prophylaxis lead to  
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increased major bleeding, causing WKHWUHDWPHQW¶V harms to exceed its benefits. The duration 
of hospitalization for patients with an acute medical illness has fallen in the US.[13]±[16] At 
the same time, the number of medical hospitalizations in patients aged 45-74 has 
increased,[17] and is likely to increase further as the population ages.[18] These changes 
increase the need for a VTE prophylaxis regimen which may protect high risk patients from 
VTE events following hospital discharge, without raising their risk of major bleeding. 
Betrixaban is a factor Xa inhibitor which was the first and only direct oral 
anticoagulant (DOAC) to be approved by the US Food and Drug Administration for 
extended-duration VTE prophylaxis of hospitalized, acutely ill medical patients.[19] Whilst 
there have been studies of extended-duration VTE prophylaxis with other DOACs, none have 
been approved in any market. Hence, it is of great interest to understand how standard-
duration VTE prophylaxis compares to betrixaban. In the Acute Medically Ill VTE 
Prevention with Extended Duration Betrixaban (APEX) study (NCT01583218), betrixaban 
demonstrated effective extended-duration VTE prophylaxis lasting up to 42 days without an 
increase in the risk of major bleeding, compared with standard-duration VTE prophylaxis 
lasting up to 14 days with enoxaparin, a low molecular weight heparin (LMWH).[20] 
However, no studies have compared betrixaban with alternative VTE prophylaxis (including 
LMWHs other than enoxaparin, unfractionated heparin (UFH), fondaparinux sodium), or 
placebo. LMWHs other than enoxaparin are of interest since they are also recommended for 
prophylactic use in the US, the UK and other markets.[21]±[23] 
The purpose of this study was to determine the relative clinical effectiveness of 
extended-duration VTE prophylaxis with betrixaban from hospitalization through post-
discharge compared with standard-duration VTE prophylaxis regimens which cease during 
hospitalization or at hospital discharge, using other available interventions, including 
LMWHs, UFH, fondaparinux sodium and placebo, for hospitalized, nonsurgical patients with 
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acute medical illness at risk of VTE evaluated 20-50 days following the initiation of 
prophylaxis. 
Methods 
A systematic literature review (SLR) was performed to identify randomized controlled trials 
(RCTs) of betrixaban and standard-duration VTE prophylaxis. This SLR was conducted to 
identify studies to be considered for inclusion in a network meta-analysis (NMA). 
Identification of relevant studies 
We sought studies which answered the following review question: 
What is the efficacy and safety of betrixaban, LMWHs, UFH, fondaparinux sodium and 
placebo in adults who are hospitalized for an acute medical condition and are at risk of 
VTE? 
We identified and updated a clinical evidence review performed in December 2008, 
which related to interventions for thromboprophylaxis in hospitalized patients and was 
performed by the National Institute of Health and Care Excellence (NICE).[24] Three search 
iterations were undertaken to update the 2008 NICE SLR, with the first performed in 
December 2016,  the second performed in December 2017 and the third performed in June 
2019. The search strategy presented in supplementary online materials (Supplementary 
material 1) was used to search EMBASE, Medline, Medline® In-Process, HTA Database, 
NHS Economic Evaluation Database and the Cochrane Central Register of Controlled Trials 
(CENTRAL) (Cochrane Library). CRPSOHPHQWDU\³grey´literature sources were also 
searched to identify data from recent or ongoing trials during the past three years that had not 
been archived in a database. Unpublished or non-MRXUQDO³JUH\´OLWHUDWXUHVRXUFHVLQFOXGHG
FOLQLFDOWULDOVJRYWKHPDQXIDFWXUHU¶VUHSRVLWRU\RIHYLdence, manufacturers of comparator 
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products¶ websites and conference proceedings. All references identified were deduplicated 
after search compilation. The first and second iteration of searches were reviewed by two 
independent health economists. Reviewers  identified relevant search results by assessing:  
title and abstract in the first pass of search results, and the entire publication during the 
second pass. Any discrepancies between the reviewers in the first and second iterations were 
discussed and resolved with a third, independent reviewer, in alignment with the Centre for 
5HYLHZVDQG'LVVHPLQDWLRQ¶VJXLGDQFHIRUXQGHUWDNLQJUHYLHZVLQKHDOWKFDUH.[25] The third 
iteration of searches was a pragmatic SLR update to ensure that the search is up to date at the 
time of preparing for this manuscript and all essential studies were included in the analyses. 
As such, it was reviewed by one health economist only at first and second pass. 
The studies were assessed by applying eligibility criteria which were defined 
according to the PICOS (population, interventions, comparators, outcomes and study type) 
principle.[25] Included studies: were performed in acute, medically ill hospitalized adult 
patients at risk of VTE; compared a combination of betrixaban, fondaparinux sodium, 
LMWHs, UFH, no treatment or placebo; reported mortality, VTE incidence or adverse 
events; and were RCTs. The full eligibility criteria can be found in supplementary online 
materials (Table S1, Supplementary material 2).  
Data extraction and quality assessment 
All studies identified by the SLR were extracted by one reviewer and assessed independently 
by another reviewer. A pre-prepared extraction grid was designed to collect data from each 
study regarding: primary study reference; eligibility criteria; settings; trial drugs; concomitant 
medications; statistical methods; participant baseline characteristics; and all relevant recorded 
outcomes. During the feasibility assessment which followed extraction, studies were assessed 
according to Australian Pharmaceutical Benefits Advisory Committee (PBAC) guidance to 
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identify heterogeneity across studies. This entailed a comparison of: study designs, 
population characteristics, treatment types and durations, and outcomes, to ensure 
comparability with the APEX study.[26] Baseline demographics which informed the 
assessment of heterogeneity are shown for all studies considered, in Table S2 (Supplementary 
Material 3). The studies were then assessed for bias using the Cochrane guidance.[27], [28] 
Statistical analysis 
Analyses were performed using WinBUGS (version 1.4.3, Imperial College and 
Medical Research Council, UK) and RStudio (version 1.0.143, RStudio, Inc., Boston, 
Massachusetts).[29], [30] WinBUGS was run via RStudio using the package 
R2WinBUGS.[31] The outcomes considered were: VTE, VTE-related death, major bleeding, 
pulmonary embolism (PE), asymptomatic deep vein thrombosis (DVT) and symptomatic 
DVT reported 20-50 days following the initiation of thromboprophylaxis. For each outcome 
analyzed, median odds ratios with 95% credible intervals (CrI) for each comparator were 
generated relative to betrixaban, since it was of interest to know how other treatments 
compared to betrixaban. Uncertainty was quantified using 95% credible intervals, which are 
the Bayesian analogue of confidence intervals, in accordance with NICE Decision Support 
Unit guidance which used this approach to quantify uncertainty of model results. All 
outcomes were evaluated using a standard Bayesian fixed effect NMA on the logit scale.[32] 
The treatment effects of all LMWHs were assumed identical, aligning with NICE clinical 
guidelines for VTE which assume a class effect among LMWHs.[22] The standard non-
informative priors were used for treatment effects and study-specific baseline effects.[32] 
Convergence of all parameters (including treatment effects, study-specific baseline effects 
and odds ratios) were assessed using trace plots and Brooks-Gelman-Rubin plots for each 
model.[33] If there were zero events, and hence convergence issues, a continuity correction 
was made.[32] To handle other issues with convergence, the variance of the prior 
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distributions were reduced. Model fit was assessed using median residual deviance and 
number of unconstrained data points. 
Sensitivity analysis 
In the base case, studies with a placebo arm which were performed prior to the year 2000, 
were excluded. The year 2000 was an arbitrary threshold between the two earliest identified 
placebo-controlled studies (Belch 1981 and PREVENT 2002), which were conducted over 
twenty years apart.[34], [35] The threshold was applied to avoid exclusion of more recent 
studies conducted since best supportive care had improved relative to older studies. These 
more recent studies were expected to show relatively small additional benefits of 
pharmacological prophylaxis compared to best supportive care, and therefore show newer 
treatments to be relatively less efficacious compared to placebo.  
7RH[DPLQHWKLVWKUHVKROG¶VHIIHFWVWXGLHVSHUIRUPHGSULRUWo 2000 that included a placebo 
arm were included in a sensitivity analysis. Additionally, to understand differences in 
treatment effect across all definitions of DVT, a sensitivity analysis was performed 
combining all DVT outcomes reported 20-50 days after initiation of thromboprophylaxis in 
one measure. If a study reported multiple definitions of DVT, each type of recorded DVT 
was considered to be from a unique study and was added to the composite measure. Finally, 
to examine the effect of only using full dose betrixaban, a sensitivity analysis was performed 
excluding all betrixaban patients with severe renal impairment or those that received a 
concomitant P-glycoprotein inhibitor who received half-doses of the study medications in the 
APEX study. 
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Results 
Systematic literature review 
The SLR identified 1,681 references. Figure 1 shows the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) diagram demonstrating the flow of 
reference identification to NMA inclusion. The 16 unique studies identified from the SLR 
which were considered for NMA inclusion evaluated betrixaban, LMWHs (enoxaparin, 
nadroparin, dalteparin and certoparin), UFH, fondaparinux sodium, and placebo.  
 
Data extraction and quality assessment 
Among the 16 studies identified, the timing of outcomes was a major confounding factor 
identified in the heterogeneity assessment. In order to appropriately compare outcomes across 
studies of betrixaban for extended duration VTE prophylaxis, it was determined that 
outcomes not reported 20-50 days following the initiation of pharmacological 
thromboprophylaxis would not be suitable for inclusion in the NMA. Nine studies were 
excluded from inclusion in the NMA on this basis.[36]±[44] Whilst study design, population 
characteristics, treatment arms and outcomes were thoroughly compared, there were no 
aspects that were deemed to be major confounding factors in the heterogeneity assessment. 
There was mild concern about variation in duration of active treatment and follow-up time, 
however this was not deemed to be limiting as all treatment durations received were within 
their license. Hence, heterogeneity assessment did not prompt exclusion of any further 
studies. 
Table 1 provides a summary of the studies included in the NMA. Supplementary 
online materials (Table S3) provides definitions of each of the outcomes included in or 
excluded from the analysis, by study. Additionally, Table S3 provides a summary of the 
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demographics of patients enrolled in each study included in the analysis. The definitions of: 
acute medically ill; average population age; and average population weight were identified as 
minor confounding factors in the heterogeneity assessment, though no study was excluded 
from the NMA on this basis. 
The results of the bias assessment are summarized in Figure 2. All studies were 
randomized, and randomization method was evaluated as appropriate where reported;[20], 
[45]±[48] Belch 1981 and PREVENT did not report the method of randomization so 
appropriateness was unclear.[34], [35] Concealment of treatment was adequate in all 
studies,[20], [35], [45], [46], [48] except Belch 1981 and Forette 1995 which were open 
label.[34], [47] In most studies, the groups enrolled were similar at baseline;[20], [35], [45], 
[48] though information on baseline characteristics was inadequate in Belch 1981, CERTIFY 
and Forette 1995.[34], [46], [47] There were equal drop-out rates amongst the study arms 
included and it does not appear that any data has been omitted from the reported results.[20], 
[34], [35], [45]±[48] The intention-to-treat (ITT) populations were reported in 
LIFENOX.[48] In APEX, ARTEMIS, CERTIFY and PREVENT, the ITT populations were 
restricted by results of a venography.[20], [35], [45], [46] The appropriate use of the ITT 
populations was not clear in Belch 1981 and Forette 1995.[34], [47] The graph displaying the 
risk of bias amongst studies included in the NMA is presented in Figure 3. 
Base case analyses results 
The network diagrams for each analysis can be found in supplementary online materials 
(Figure S1-S8, Supplementary material 5). 
Four studies and a total of 14,024 participants were included in the analysis of 
VTE.[20], [35], [45], [46] There were significantly higher odds (median odds [95% CrI]) of a 
VTE with LMWHs (OR, 1.38; 95% CrI, 1.12-1.70), with UFH (OR, 1.60; 95% CrI, 1.05-
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2.46), or with placebo (OR, 2.37; 95% CrI 1.55-3.66), relative to betrixaban (Figure 4A). 
There was not a significant difference between betrixaban and fondaparinux sodium in the 
odds of VTE.  
Five studies and a total of 23,346 participants were included in the VTE-related death 
analysis.[20], [35], [45], [46], [48] There were significantly higher odds of a VTE-related 
death with placebo relative to betrixaban (OR, 7.76; 95% CrI, 2.14-34.40) (Figure 4B). The 
odds of a VTE-related death with LMWHs, UFH, and fondaparinux sodium were not 
significantly different to betrixaban.  
Four studies and a total of 14,283 participants were included in the major bleeding 
analysis.[20], [35], [46], [47] There were no significant differences in the odds of major 
bleeding with placebo, LMWHs, or UFH compared with betrixaban (Figure 4C). It was not 
possible to form a comparison against fondaparinux sodium as major bleeding was only 
reported as an outcome in ARTEMIS up to 2 days after treatment, which is a maximum of 16 
days ± outside of the Day 20-50 inclusion.  
Four studies and a total of 14,855 participants were included in the symptomatic DVT 
analysis.[20], [35], [45], [46] There was no significant difference in the odds of symptomatic 
DVT with betrixaban compared with any of the included comparators. The median odds ratio 
of comparators relative to betrixaban was greater than 1.5 in all cases (Figure 4D), suggesting 
higher (albeit non-significant) odds of symptomatic DVT with placebo, LMWHs, UFH, and 
fondaparinux sodium compared with betrixaban.  
Three studies and a total of 13,142 participants were included in the asymptomatic 
DVT analysis.[20], [35], [46] There were significantly higher odds of an asymptomatic DVT 
with LMWHs (OR, 1.34; 95% CrI, 1.07-1.69), UFH (OR, 1.63; 95% CrI, 1.04-2.57), and 
placebo (OR, 2.81; 95% CrI, 1.68-4.73) (Figure 4E). It was not possible to form a 
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comparison against fondaparinux sodium as asymptomatic DVT was only measured to Day 
15 in ARTEMIS.  
Five studies and a total of 14,898 participants were included in the PE analysis.[20], 
[35], [45]±[47] The odds of a PE were not significantly different with betrixaban compared 
with any of the included comparators (Figure 4F). The median odds ratio of LMWHs, UFH, 
and placebo relative to betrixaban was greater than 1.0 (Figure 4F), suggesting higher (albeit 
non-significant) odds of PE with placebo, LMWHs, and UFH compared with betrixaban. On 
the other hand, the median odds ratio of fondaparinux sodium relative to betrixaban was less 
than 1.0 (Figure 4F), suggesting lower (albeit non-significant) odds of PE with fondaparinux 
sodium compared with betrixaban.  
For each outcome, the median residual deviance (7.4, 10.1, 6.6, 5.3 and 10.1 for VTE, 
major bleeding, symptomatic DVT, asymptomatic DVT, and PE, respectively) was close to 
the number of data points used (8, 8, 8, 6 and 10 respectively). This indicates that the models 
are a good fit to the data. For VTE-related death, the median residual deviance was 21.2, 
which is much higher than the number of data points used (10). This indicates that the VTE-
related death model may not be a good fit to the data. 
Sensitivity analysis results 
Only one study, Belch 1981, was completed before 2000 with a placebo arm. The only 
outcome that this study contributed to was PE. Therefore, the PE analysis was rerun with 
Belch 1981 included as a sensitivity analysis including a total of 14,998 participants.[20], 
[34], [35], [45]±[47] The odds ratio of a PE with placebo relative to betrixaban was greater 
than in the base case, though it was lower for the other comparators. The significance of the 
results did not change and neither did the preference for any treatment over betrixaban. 
The sensitivity analysis that considered all types of recorded DVT included eleven 
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different DVT results from five studies.[20], [35], [45]±[47] There were 37,249 participants 
included in the analysis. The odds of any type of DVT were significantly greater with 
LMWHs (OR, 1.36; 95% CrI, 1.10-1.70), UFH (OR, 1.63; 95% CrI, 1.20-2.21) and placebo, 
(OR, 2.74; 95% CrI, 1.90-4.00) compared with betrixaban. Though the median odds ratio of 
any DVT relative to betrixaban was above one for fondaparinux sodium, the difference in 
odds was not significant. 
For the sensitivity analyses considering only patients on the full study dose from the 
APEX study, the total number of studies included in each analysis remained the same. There 
were, however, fewer patients for each analysis due to the exclusion of betrixaban patients 
with severe renal impairment and patients taking P-glycoprotein inhibitors from the APEX 
study. There were 12,387, 21,709, 12,738, 11,505, 13,218, and 13,261 participants included 
in the analysis of VTE, VTE-related death, major bleeding, asymptomatic DVT, symptomatic 
DVT, and PE, respectively. Mostly, the significance of differences between treatments 
remained the same as in the full-population analyses. The only changes were of the odds ratio 
of a symptomatic DVT with placebo (OR, 3.08; CrI, 1.05-9.28) and of a PE with LMWH 
(OR, 3.74; CrI, 1.36-13.32) relative to betrixaban. This sensitivity analysis showed 
significantly lower odds of a VTE for betrixaban compared with placebo and LMWH.  
Discussion 
The results of the NMA showed a significant reduction in VTE morbidity and 
mortality with betrixaban compared with LMWH, UFH, and placebo. Reducing VTE events 
would reduce recurrent VTE morbidity and complications such as CTEPH and PTS, which 
are very costly to manage and severely impact quality of life.[49], [50] This further indicates 
that extended VTE prophylaxis with betrixaban may lead to prolonged patient health benefits. 
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Additionally, the results showed a significant reduction in asymptomatic DVT with 
betrixaban compared with LMWHs, UFH, and placebo. Asymptomatic DVT is associated 
with chronic complications such as PTS,[51] and may progress to symptomatic DVT,[52] 
which requires anticoagulation treatment lasting months and leads to rehospitalization for 
many patients. Symptomatic DVT is also associated with a risk of recurrent VTE and 
complications such as PTS. It is evident that reducing asymptomatic DVT may reduce risk of 
future, more serious events which are associated with poorer quality of life and increased 
healthcare costs. Furthermore, following an asymptomatic DVT event, patients have an 
increased risk of death compared with patients who have not experienced a DVT event.[53]  
There was a strong trend of fewer symptomatic DVT and PE events with betrixaban 
compared with the other treatments available, with the point estimate of all odds ratios 
favoring betrixaban with few exceptions. Many of the results from the analysis did not 
achieve statistical significance, which may be due to a lack of head-to-head evidence. The 
conclusions of the analysis could have been stronger had direct evidence comparing 
betrixaban to placebo, UFH or fondaparinux sodium been available. 
This analysis demonstrated no significant difference between betrixaban and any of 
the comparators for the occurrence of major bleeding. This benefit in safety was also seen in 
the APEX study, as there was no significant difference in major bleeding between betrixaban 
and enoxaparin.[20] Adverse events which are associated with VTE prophylaxis such as 
major bleeding (which includes intracranial hemorrhage) can be costly to treat and are 
associated with reduced long term quality of life. However non-major bleeding is increased in 
extended prophylaxis and therefore appropriate management of the risk-benefit ratio and 
identification of at-risk patients for extended VTE-prophylaxis are essential in addressing the 
growing need for VTE prophylaxis extending beyond hospitalization.[54]±[56]  
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The results of the NMA for betrixaban versus fondaparinux sodium are uncertain. The 
analysis showed no significant difference between the two regimens. This may indicate that 
betrixaban is not superior to fondaparinux sodium as extended-duration prophylaxis. 
However, the treatment effect of fondaparinux sodium was based only on the ARTEMIS 
trial. This trial had fewer participants compared with other trials included in the NMA. All 
DVT events recorded in the first 15 days were asymptomatic DVT detected by venography 
and the only symptomatic events recorded in the primary outcome of the trial were 
adjudicated fatal PE. Furthermore there were no asymptomatic events recorded after the first 
15 days that could be included in the analysis. Therefore, inclusion of ARTEMIS focused on 
reports of symptomatic events which were measured until day 32. At the end of follow-up the 
placebo arm reported twice as many fatal PE and four times more non-fatal PE events than 
the fondaparinux sodium arm, and both arms reported zero incidence of symptomatic DVT. 
These factors have contributed to uncertainty in the results for fondaparinux sodium in the 
NMA and may have led to an overestimation of the treatment effect associated with 
fondaparinux sodium as the incidence of asymptomatic events has not been considered due to 
incompatible timing. Of note however, a larger proportion of patients in the fondaparinux 
sodium arm experienced fatal PE (0.7% fatal PE for fondaparinux patients compared to, for 
example, 0.3% fatal VTE for betrixaban patients in APEX); as such, fewer patients in this 
arm remained alive for the duration of the trial to be at risk of non-fatal VTE events, possibly 
causing the burden of such events to be underrepresented relative to the placebo arm.[39] 
The main limitation of this analysis is the small number of studies that were available 
for comparison. In particular, studies of DOACs for extended VTE prophylaxis were not 
considered as they are not approved in this indication in any market, and many studies 
identified by the SLR were not suitable for comparison with the results of the APEX study as 
outcomes were not reported within the interval of 20-50 days following prophylaxis 
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initiation.[36]±[44] Overall however, the timeframe of 20-50 days following the initiation of 
VTE prophylaxis enabled the selection of the most suitable and comparable studies based on 
the time at which patients were assessed in the APEX study (following completion of their 
extended-duration VTE prophylaxis regimen), enabling comparisons to be drawn with 
betrixaban.  
Another limiting factor was the lack of head-to-head data available for betrixaban; 
had there been more studies completed for betrixaban against other treatments there would 
have been more data to form stronger conclusions.  
Additionally, no adjustment was made for the duration of treatment in the different 
studies. This may have caused overestimation of the benefits of longer-duration treatment, 
since such regimens provided a longer timeframe for treatment benefit to be observed. 
However, the treatment durations compared were all within their licensed indication, and 
therefore the differences in treatment duration are inherently linked to the differences in 
treatment effect. 
Finally, the exclusion of studies containing placebo treatment conducted prior to the 
year 2000 to account for changing clinical practice in best supportive care may have caused 
overlooked bias due to changing methods to confirm clinical endpoints in studies over time. 
However, as all treatment arms within a study would use the same diagnostic measures, 
systematic differences in the method of diagnosing patients should not have affected the 
estimates of incremental treatment effect observed. Moreover, a feasibility assessment was 
conducted to investigate such heterogeneity, among other factors, and no major differences in 
the endpoint measures between studies were identified for relevant endpoints for each study. 
A sensitivity analysis including the Belch 1981 study confirmed that results were robust to 
the year of publication among studies included.The use of a fixed effect NMA enabled 
estimation of treatment effects in the included studies. A random effects model would be 
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required to generalize the results beyond the included studies and remove any bias that may 
be attributed to anticipated confounding factors between the studies. However, due to the 
small number of studies and nature of VTE events, informative priors using external 
information would be needed for this kind of analysis. As such, fixed effect models have 
been used, limiting assessment of between-study heterogeneity, possibly producing 
artificially small credible intervals for results. The small number of studies also restricted the 
use of funnel plots for robust bias and quality assessment. 
Conclusions 
In this indirect comparison, extended-duration VTE prophylaxis from hospital admission 
through post-discharge with betrixaban was a comparatively safe and effective regimen. 
Results showed that betrixaban extended-duration VTE prophylaxis provides relative benefit 
with respect to the efficacy and safety outcomes considered, when compared to regimens for 
standard VTE prophylaxis. Given the need for an effective extended-duration VTE 
prophylaxis with a good safety profile, betrixaban shows potential to contribute to reducing 
the burden of VTE in hospitalized, nonsurgical patients with acute medical illness at risk of 
VTE, however in the absence of direct comparative evidence stronger conclusions cannot be 
drawn. 
WORD COUNT: 3,759/10,800 
Transparency 
Declaration of Funding 
This research was supported by Portola Pharmaceuticals, Inc. 
18 
 
Declaration of financial/other relationships 
VL, HG and MF are employees of FIECON Ltd, a health-economics outcomes research 
agency, which performed the analyses presented in the manuscript, funded by Portola 
Pharmaceuticals, Inc. RN and IB were employees of Portola Pharmaceuticals, Inc, at the time 
of the research project. 
SR is a Research Fellow at The University of Sheffield and performed the analyses presented 
in the manuscript in collaboration with FIECON Ltd, funded by FIECON Ltd. 
ATC has received consulting fees, research support, and honoraria from AbbVie, ACI 
Clinical, Aspen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Boston Scientific, CSL 
Behring, Daiichi-Sankyo, GlaxoSmithKline, GLG, Guidepoint Global, Johnson and Johnson, 
Leo Pharma, Medscape, McKinsey, Navigant, ONO, Pfizer, Portola, Sanofi, Takeda, 
Temasek Capital, and TRN. 
Author contributions 
VL, HG, MF, AC and SR were involved in the design and execution of the analysis. All 
authors were involved in the interpretation of the results, drafting and revising this 
manuscript, and provided final approval of the version to be published. All authors vouch for 
the accuracy of the content included in the full manuscript. 
Acknowledgements 
Augusta Connor is thanked for her editing to bring the publication to press. 
Previous Presentations 
The base case results were presented in a poster submitted to both the American College of 
Clinical Pharmacy (ACCP) and the Academy of Managed Care Pharmacy in 2018. The 
abstract for the poster was published in the abstract book of the conference of ACCP. There 
19 
 
has not yet been a full publication of the results. 
Data Availability Statement 
Raw data were generated at Portola Pharmaceuticals. Derived data supporting the findings of 
this study are available from the corresponding author (VL) on request.  
20 
 
References 
[1] *3LD]]D-)DQLNRV0=D\DUX]Q\DQG6=*ROGKDEHU³9HQRXVWKURPERHPEROLF
eveQWVLQKRVSLWDOLVHGPHGLFDOSDWLHQWV´Thromb. Haemost., vol. 102, no. 3, pp. 505±
510, Sep. 2009. 
[2] -$+HLW$7&RKHQDQG)$$QGHUVHQ-U³(VWLPDWHGDQQXDOQXPEHURILQFLGHQW
and recurrent, non-IDWDODQGIDWDOYHQRXVWKURPERHPEROLVP97(HYHQWVLQWKH86´
Blood, no. 106, p. 910, 2005. 
[3] -$+HLW)$6SHQFHUDQG5+:KLWH³7KHHSLdemiology of venous 
WKURPERHPEROLVP´J Thromb Thrombolysis, vol. 41, pp. 3±14, 2016. 
[4] V. Pengo et al.³,QFLGHQFHRIFKURQLFWKURPERHPEROLFSXOPRQDU\K\SHUWHQVLRQDIWHU
SXOPRQDU\HPEROLVP´N Engl J Med, vol. 350, no. 22, pp. 2257±2264, May 2004. 
[5] P. Prandoni et al.³7KHFOLQLFDOFRXUVHRIGHHS-vein thrombosis. Prospective long-term 
follow-XSRIV\PSWRPDWLFSDWLHQWV´Haematologica, vol. 82, no. 4, pp. 423±428, 
Aug. 1997. 
[6] A. C. Spyropoulos et al.³3UHGLFWLYHDQGDVVRFLDWLYHPRGHOVWRLGHQWLfy hospitalized 
PHGLFDOSDWLHQWVDWULVNIRU97(´Chest, vol. 140, no. 3, pp. 706±714, Sep. 2011. 
[7] $1$PLQ+9DUNHU13ULQFLF-/LQ67KRPSVRQDQG6-RKQVWRQ³'XUDWLRQRI
venous thromboembolism risk across a continuum in medically ill hospitalized 
SDWLHQWV´J Hosp Med, vol. 7, no. 3, pp. 231±238, Mar. 2012. 
[8] 73HQGHUJUDIW0$WZRRG;/LX+3KDWDN/=/LXDQG*2VWHU³&RVWRIYHQRXV
WKURPERHPEROLVPLQKRVSLWDOL]HGPHGLFDOO\LOOSDWLHQWV´Am J Health Syst Pharm, vol. 
70, no. 19, pp. 1681±1687, Oct. 2013. 
[9] -$+HLW'-&UXVDQ$$$VKUDQL703HWWHUVRQDQG.5%DLOH\³(IIHFWRID
near-universal hospitalization-based prophylaxis regimen on annual number of venous 
WKURPERHPEROLVPHYHQWVLQWKH86´Blood, vol. 130, no. 2, pp. 109±114, 13 2017. 
[10] A. T. Cohen et al.³5LYDUR[DEDQIRUWKURPERSURSK\OD[LVLQDFXWHO\LOOPHGLFDO
SDWLHQWV´N Engl J Med, vol. 368, no. 6, pp. 513±523, Feb. 2013. 
[11] S. Z. Goldhaber et al.³$SL[DEDQYHUVXVHQR[DSDULQIRUWKURPERSURSKylaxis in 
PHGLFDOO\LOOSDWLHQWV´N Engl J Med, vol. 365, no. 23, pp. 2167±2177, Dec. 2011. 
[12] R. D. Hull et al.³([WHQGHG-duration venous thromboembolism prophylaxis in acutely 
LOOPHGLFDOSDWLHQWVZLWKUHFHQWO\UHGXFHGPRELOLW\DUDQGRPL]HGWULDO´Ann Intern Med, 
vol. 153, no. 1, pp. 8±18, 2010. 
[13] Weiss AJ, Elixhauser A, for Agency for Healthcare Research and Quality. Overview of 
hospital stays in the United States, 2012 (2014). https://www.hcup-
us.ahrq.gov/reports/statbriefs/sb180-Hospitalizations-United-States-2012.pdf (accessed 
2018 March 20). 
[14] Organisation for Economic Co-operation and Development. Health at a glance 2017: 
OECD indicators. https://www.oecd-ilibrary.org/docserver/health_glance-2017-
en.pdf?expires=1536312324&id=id&accname=guest&checksum=9A2183B01DA4247F
63CA207618BB50BB (accessed 2018 March 20). 
[15] US Department of Health and Human Services. CMS Statistics 2015. 
https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-
Reports/CMS-Statistics-Reference-Booklet/Downloads/2015CMSStatistics.pdf 
(accessed 2018 May 24). 
[16] US Department of Health and Human Services. CMS Statistics 2016. 
https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-
Reports/CMS-Statistics-Reference-Booklet/Downloads/2016_CMS_Stats.pdf (accessed 
2018 May 24). 
21 
 
[17] Agency for Healthcare Research and Quality, Rockville, MD. Statistical Brief #225: 
Healthcare Cost and Utilization Project (HCUP) (2017).  www.hcup-
us.ahrq.gov/reports/statbriefs/sb225-Inpatient-US-Stays-Trends.jsp. (accessed 2018 
June 28). 
[18] Jacobsen LA, Kent M, Lee M and Mather M, for the Population Reference Bureau. 
$PHULFD¶V$JLQJ3RSXODWLRQ3RSXODWLRQ%XOOHWLQQR
https://assets.prb.org/pdf11/aging-in-america.pdf (accessed 2018 June 28). 
[19] Food and Drug Administration. FDA approved betrixaban (BEVYXXA, Portola) for the 
prophylaxis of venous thromboembolism (VTE) in adult patients. 
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564422.htm 
(accessed 2018 March 20). 
[20] A. T. Cohen et al.³([WHQGHGWKURPERSURSK\OD[LVZLWKEHWUL[DEDQLQDFXWHO\LOOPHGLFDO
SDWLHQWV´N Engl J Med, vol. 375, no. 6, pp. 534±544, Aug. 2016. 
[21] ASH Clinical Practice Guidelines on Venous Thromboembolism, 04-Feb-2019. 
[Online]. Available: /VTE/. [Accessed: 26-Feb-2019]. 
[22] 1,&(³&OLQLFDO*XLGHOLQH9HQRXVWKURPERHPEROLVPLQRYHUVUHGXFLQJWKHULVNRI
hospital-DFTXLUHGGHHSYHLQWKURPERVLVRUSXOPRQDU\HPEROLVP8SGDWH´
[Online]. Available: https://www.nice.org.uk/guidance/indevelopment/gid-
cgwave0795/consultation/html-content-2. 
[23] A. Johnston et al.³$V\VWHPDWLFUHYLHZRIFOLQLFDOSUDFWLFHJXLGHOLQHVRQWKHXVHRIORZ
molecular weight heparin and fondaparinux for the treatment and prevention of venous 
thromboembolism: Implications for research and policy decision-PDNLQJ´PLoS One, 
vol. 13, no. 11, Nov. 2018. 
[24] NICE. ³Venous thromboembolism: reducing the risk for patients in hospital: Clinical 
JXLGHOLQHQLFHRUJXNJXLGDQFHFJDFFHVVHG2FWREHU´ 
[25] &HQWUHIRU5HYLHZVDQG'LVVHPLQDWLRQ6\VWHPDWLFUHYLHZV&5'¶VJXLGance for 
undertaking reviews in health care (2009). 
https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf (accessed 2016 October 
20). 
[26] Pharmaceutical Benefits Advisory Committee. Guidelines for preparing a submission to 
the PBAC (2010). https://pbac.pbs.gov.au/content/information/files/pbac-guidelines-
version-5.pdf (accessed 2017 June 26). 
[27] Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, 
The Cochrane Collaboration, 2014. 
[28] Higgins JPT, Green S (editors), for the Cochrane Collection. Cochrane Handbook for 
Systematic Reviews of Interventions Version 5.1.0: Chapter 8: Assessing risk of bias in 
included studies (2011). www.handbook.cochrane.org (accessed 2018 June 5). 
[29] D. J. Lunn, A. Thomas, N. Best, and D. SpiegelhDOWHU³:LQ%8*6- A Bayesian 
PRGHOOLQJIUDPHZRUN&RQFHSWVVWUXFWXUHDQGH[WHQVLELOLW\´Statistics and Computing, 
vol. 10, no. 4, pp. 325±337, Oct. 2000. 
[30] RStudio Team. RStudio: Integrated Development for R. RStudio, Inc., Boston, (2016). 
http://www.rstudio.com/ (accessed 2017 October 28). 
[31] 66WXUW]8/LJJHVDQG$*HOPDQ³5:LQ%8*6$3DFNDJHIRU5XQQLQJ
:LQ%8*6IURP5´Journal of Statistical Software, vol. 12, no. 3, pp. 1±16, 2005. 
[32] Dias S., Welton N.J., Sutton A.J., Aeds A.E. NICE DSU Technical Support Document 
2: A generalised linear modelling framework for pairwise and network meta-analysis of 
randomised controlled trials (September 2016). http://scharr.dept.shef.ac.uk/nicedsu/wp-
content/uploads/sites/7/2017/05/TSD2-General-meta-analysis-corrected-
2Sep2016v2.pdf (accessed 2017 July 78). 
22 
 
[33] 6%URRNVDQG$*HOPDQ³*HQHUDO0HWKRGVIRU0RQLWRULQJ&RQYHUJHQFHRI,WHUDWLYH
6LPXODWLRQV´Journal of Computational and Graphical Statistics, vol. 7, no. 4, pp. 434±
455, 1998. 
[34] J. J. BeOFK*'/RZH$*:DUG&')RUEHVDQG&53UHQWLFH³3UHYHQWLRQRI
deep vein thrombosis in medical patients by low-GRVHKHSDULQ´Scott Med J, vol. 26, no. 
2, pp. 115±117, Apr. 1981. 
[35] A. Leizorovicz et al.³5DQGRPL]HGSODFHER-controlled trial of dalteparin for the 
SUHYHQWLRQRIYHQRXVWKURPERHPEROLVPLQDFXWHO\LOOPHGLFDOSDWLHQWV´Circulation, 
vol. 110, no. 7, pp. 874±879, Aug. 2004. 
[36] -)%HUJPDQQDQG(1HXKDUW³$PXOWLFHQWHUUDQGRPL]HGGRXEOH-blind study of 
enoxaparin compared with unfractionated heparin in the prevention of venous 
thromboembolic disease in elderly in-patients bedridden for an acute medical illness: 
7KHHQR[DSDULQLQPHGLFLQHVWXG\JURXS´Thromb. Haemost., vol. 76, no. 4, pp. 529±
534, Oct. 1996. 
[37] ,0DKp-)%HUJPDQQ3G¶$]pPDU--9DLVVLHDQG&&DXOLQ³/DFNRIHIIHFWRID
low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-
patients: a prospective randomised double-EOLQGVWXG\´Eur. J. Clin. Pharmacol., vol. 
61, no. 5±6, pp. 347±351, Jul. 2005. 
[38] -+DUHQEHUJ35RHEUXFNDQG'/+HHQH³6XEFXWDQHRXVORZ-molecular-weight 
heparin versus standard heparin and the prevention of thromboembolism in medical 
inpatients: The heparin study in internal medicine grouS´Haemostasis, vol. 26, no. 3, 
pp. 127±139, Jun. 1996. 
[39] S. V. Ishi et al.³5DQGRPLVHGFRQWUROOHGWULDOIRUHIILFDF\RIXQIUDFWLRQDWHGKHSDULQ
(UFH) versus low molecular weight heparin (LMWH) in thrombo-SURSK\OD[LV´
J.Assoc.Physicians India, vol. 61, no. 12, pp. 882±886, 2013. 
[40] M. M. Samama et al.³$FRPSDULVRQRIHQR[DSDULQZLWKSODFHERIRUWKHSUHYHQWLRQRI
venous thromboembolism in acutely ill medical patients: prophylaxis in medical patients 
ZLWKHQR[DSDULQVWXG\JURXS´N. Engl. J. Med., vol. 341, no. 11, pp. 793±800, Sep. 
1999. 
[41] F.-X. Kleber et al.³5DQGRPL]HGFRPSDULVRQRIHQR[DSDULQZLWKXQIUDFWLRQDWHGKHSDULQ
for the prevention of venous thromboembolism in medical patients with heart failure or 
VHYHUHUHVSLUDWRU\GLVHDVH´Am. Heart J., vol. 145, no. 4, pp. 614±621, Apr. 2003. 
[42] (/HFKOHU:6FKUDPPDQG&:)ORVEDFK³7KHYHQRXVWKURPERWLFULVNLQQRQ-
surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-
weight heparin (enoxaparin). The Prime 6WXG\*URXS´Haemostasis, vol. 26 Suppl 2, 
pp. 49±56, 1996. 
[43] F. A. Lederle et al.³7KHSURSK\OD[LVRIPHGLFDOSDWLHQWVIRUWKURPERHPEROLVPSLORW
VWXG\´Am. J. Med., vol. 119, no. 1, pp. 54±59, Jan. 2006. 
[44] S. M. Schellong et al.³$QRSHQ-label comparison of the efficacy and safety of 
certoparin versus unfractionated heparin for the prevention of thromboembolic 
FRPSOLFDWLRQVLQDFXWHO\LOOPHGLFDOSDWLHQWV&(57$,1´Expert Opin.Pharmacother., 
vol. 11, no. 18, pp. 2953±2961, 2010. 
[45] A. T. Cohen et al.³(IILFDF\DQGVDIHW\RIIRQGDSDULQX[IRUWKHSUHYHQWLRQRIYHQRXV
WKURPERHPEROLVPLQROGHUDFXWHPHGLFDOSDWLHQWVUDQGRPLVHGSODFHERFRQWUROOHGWULDO´
BMJ, vol. 332, no. 7537, pp. 325±329, Feb. 2006. 
[46] H. Riess et al.³$UDndomized, double-blind study of certoparin vs. unfractionated 
heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: 
&(57,)<6WXG\´J. Thromb. Haemost., vol. 8, no. 6, pp. 1209±1215, Jun. 2010. 
23 
 
[47] B. Forette and Y. WolmarN³&DOFLXPQDGURSDULQLQWKHSUHYHQWLRQRIWKURPERHPEROLF
GLVHDVHLQHOGHUO\VXEMHFWV6WXG\RIWROHUDQFHWUDQVODWHGE\(0%$6(´Presse Med, 
vol. 24, no. 12, pp. 567±571, Mar. 1995. 
[48] A. K. Kakkar, C. Cimminiello, S. Z. Goldhaber, R. Parakh, C. Wang, and J. F. 
%HUJPDQQ³/RZ-molecular-weight heparin and mortality in acutely ill medical 
SDWLHQWV´N.Engl.J.Med., vol. 365, no. 26, pp. 2463±2472, 2011. 
[49] T. Lanitis et al.³&RVW-effectiveness of apixaban versus low molecular weight 
heparin/vitamin k antagonist for the treatment of venous thromboembolism and the 
SUHYHQWLRQRIUHFXUUHQFHV´BMC Health Serv Res, vol. 17, p. 74, Jan. 2017. 
[50] 53HVDYHQWRDQG33UDQGRQL³3UHYHQWLRQDQGWUHDWPHQWRIWKHSRVW-thrombotic 
syndrome and of the chronic thrombRHPEROLFSXOPRQDU\K\SHUWHQVLRQ´Expert Rev 
Cardiovasc Ther, vol. 13, no. 2, pp. 193±207, Feb. 2015. 
[51] -.HOO\$5XGG55/HZLVDQG%-+XQW³6FUHHQLQJIRUVXEFOLQLFDOGHHS-vein 
WKURPERVLV´QJM, vol. 94, no. 10, pp. 511±519, Oct. 2001. 
[52] 0'HQQLV10RUGL&*UDKDP36DQGHUFRFNDQG&/276WULDOVFROODERUDWLRQ³7KH
timing, extent, progression and regression of deep vein thrombosis in immobile stroke 
SDWLHQWVREVHUYDWLRQDOGDWDIURPWKH&/276PXOWLFHQWHUUDQGRPL]HGWULDOV´J. Thromb. 
Haemost., vol. 9, no. 11, pp. 2193±2200, Nov. 2011. 
[53] P. T. Vaitkus et al.³0RUWDOLW\UDWHVDQGULVNIDFWRUVIRUDV\PSWRPDWLFGHHSYHLQ
WKURPERVLVLQPHGLFDOSDWLHQWV´Thromb. Haemost., vol. 93, no. 1, pp. 76±79, Jan. 
2005. 
[54] M. C. Christensen, S. Mayer, and J.-0)HUUDQ³4XDOLW\RIOLIHDIWHULQWUDFHUHEUDO
KHPRUUKDJHUHVXOWVRIWKHIDFWRUVHYHQIRUDFXWHKHPRUUKDJLFVWURNH)$67WULDO´
Stroke, vol. 40, no. 5, pp. 1677±1682, May 2009. 
[55] %2+WWHU-0*LOVEDFKDQG,.UHLWVFKPDQQ³4XDlity of life and cognitive deficits 
DIWHUVXEDUDFKQRLGKDHPRUUKDJH´British Journal of Neurosurgery, vol. 9, no. 4, pp. 
465±476, Jan. 1995. 
[56] $6KDK$6KHZDOH&-+D\HVDQG%&0DUWLQ³&RVW-effectiveness of oral 
anticoagulants for ischemic stroke prophylaxis among nonvalvular atrial fibrillation 
SDWLHQWV´Stroke, vol. 47, no. 6, pp. 1555±1561, Jun. 2016. 
24 
 
Figures 
Figure 1. PRISMA diagram 
Figure 2. Results of the bias assessmenta 
aITT=intention-to-treat 
Figure 3. Risk of bias grapha 
aITT=intention-to-treat 
Figure 4. Base case results of the network meta-analysis 
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Tables 
Table 1. Summary of studies included in the network meta-analysisa 
Study Key eligibility criteria Interventions Baseline 
characteristics 
Outcomes 
analyzed 
Setting Reference 
APEX $JHG\HDUVFDXVHRIKRVSLWDOL]DWLRQHLWKHU
acute heart failure, acute respiratory failure, acute 
infection, acute rheumatic disorders or acute 
ischemic stroke; at least one additional VTE risk 
IDFWRURIHLWKHU\HDUVRU-74 years with D-
GLPHU8/1RU-59 with D-GLPHU8/1
and history of VTE or cancer; expected to be 
LPPRELOL]HGIRUGD\V 
Betrixaban 80 mg once 
daily (loading dose of 
160 mg for first 
dose)for 35-42 days 
(n=3,759) Enoxaparin 
40 mg once daily for 
10±4 days (n=3,754) 
Age 76 years; Male 
45%; Weight 80 kg 
VTE, VTE 
related death, 
major bleeding, 
PE, 
asymptomatic 
and 
symptomatic 
DVT 
Patients were 
enrolled from 35 
countries in 
North America, 
Europe, South 
America, South 
Africa, Asia and 
Australia 
[20] 
ARTEMIS $JHG\HDUVDFXWHO\LOOZLWKFRQJHVWLYHKHDUW
failure, or acute respiratory illness with chronic 
Fondaparinux sodium 
2.5 mg once daily for 
Age 75 years; Male 
42%; Weight 70 kg 
VTE, VTE 
related death, 
35 centres in 
eight countries 
[45] 
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lung disease, or clinically diagnosed acute 
infection or inflammatory disorder; expected be 
LPPRELOL]HGIRUGD\V 
6-14 days (n=429) 
Placebo once daily for 
6-14 days (n=420) 
PE, 
symptomatic 
DVT 
Belch 1981 $JHGDQG\HDUVDGPLWWHGWRKRVSLWDO
with heart failure or chest infection. 
UFH 5000 units/8 
hours until mobile 
(n=50) No prophylaxis 
(n=50) 
Age 66 years; Male 
69%; Weight 22% 
obese 
PEb 1 centre in 
Scotland 
[34] 
CERTIFY HosSLWDOL]HGPHGLFDOSDWLHQWV\HDUVDFXWH
medical illness; significant decrease in mobility 
H[SHFWHGIRUGD\V 
Certoparin 3000 units 
once daily (n=1,624) 
for 8-20 days UFH 
5000 units/8 hours 
(n=1,615) for 8-20 
days 
Age 79 years; Male 
41%; Weight 72 kg 
VTE, VTE 
related death, 
major bleeding, 
PE, 
symptomatic 
and 
asymptomatic 
DVT 
Recruited from 
172 centres 
between January 
2007 and June 
2009 
[46] 
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Forette 
1995 
$JHG\HDUVDGPLWWHGWo hospital for an 
estimated minimum duration of 4 weeks for a 
recent and presumed transient decrease in their 
locomotor autonomy; absence of existing DVT. 
Nadroparin 3075 units 
per day for 28 days 
(n=146) UFH 5000 
units twice daily for 28 
days (n=149) 
Age 83 years; Male 
75%; Weight 59 kg 
Major bleeding, 
PE, allc DVT 
Hospital setting 
(35 centres in 
France) 
[47] 
LIFENOX $JHG\HDUVKRVSLWDOL]HGIRUDFXWH
decompensation of heart failure, active cancer 
(unless for planned chemotherapy), or severe 
systemic infection; additional risk factor of 
chronic pulmonary disease, or obesity, or history 
RI97(RUDJHG\HDUVH[SHFWHG
hospitalization of at least 6 days. 
Enoxaparin 40 mg 
once daily for 6-14 
days (n=4,174) 
Placebo once daily for 
6-14 days (n=4,145) 
Age 65 years; Male 
63%; BMI 23 
VTE related 
death 
Hospital setting. 
193 sites in 
China, India, 
Korea, Malaysia, 
Mexico, the 
Philippines, and 
Tunisia. 
Recruitment 
began 
[48] 
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in January 2008 
and was 
completed in 
September 
2010 
PREVENT $JHG\HDUVDFXWHPHGLFDOFRQGLWLRQZLWK
projected hospitalization of 4 days and 3 days of 
prior immobilization; hospitalization for acute 
congestive heart failure; acute respiratory failure; 
infection without septic shock; acute 
rheumatologic disorders; inflammatory bowel 
disease. 
Dalteparin 5000 units 
once daily for 14 days 
(n=1,856) Placebo 
once daily for 14 days 
(n=1,850) 
Age 69 years; Male 
48%; BMI 27 
VTE, VTE 
related death, 
major bleeding, 
PE, 
symptomatic 
and 
asymptomatic 
DVT  
Between July 
2001 and April 
2002, 3706 
patients were 
enrolled at 219 
study centres in 
26 countries 
[35] 
aVTE = venous thromboembolism, ULN = upper limit of normal,  DVT = deep vein thrombosis, PE = pulmonary embolism, UFH = unfractionated heparin, 
BMI = body mass index 
29 
 
bonly included as a sensitivity analysis in this network meta-analysis 
cthe type of DVT reported in Forette 1995 was not specified so it could only be considered for the all DVT analysis 
